Decheng Capital Management Iii (Cayman), LLC Argenx Se Transaction History
Decheng Capital Management Iii (Cayman), LLC
- $181 Million
- Q3 2023
A detailed history of Decheng Capital Management Iii (Cayman), LLC transactions in Argenx Se stock. As of the latest transaction made, Decheng Capital Management Iii (Cayman), LLC holds 27,429 shares of ARGX stock, worth $14.7 Million. This represents 7.46% of its overall portfolio holdings.
Number of Shares
27,429
Previous 27,429
-0.0%
Holding current value
$14.7 Million
Previous $10.7 Million
26.15%
% of portfolio
7.46%
Previous 5.67%
Shares
2 transactions
Others Institutions Holding ARGX
# of Institutions
371Shares Held
31.4MCall Options Held
303KPut Options Held
429K-
Price T Rowe Associates Inc Baltimore, MD5.6MShares$3 Billion0.29% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$1.88 Billion2.39% of portfolio
-
Janus Henderson Group PLC London, X02.47MShares$1.32 Billion0.58% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.92MShares$1.03 Billion0.52% of portfolio
-
Capital World Investors Los Angeles, CA1.51MShares$810 Million0.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $29.7B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...